Cedars Sinai Intellectual Property Co - 08 Mar 2023 Form 4 Insider Report for Prometheus Biosciences, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 08 Mar 2023
Net transaction value: -$99,120,350
SEC form: 4
Accepted by SEC: 08 Mar 2023, 20:30:17 UTC
Prior SEC filing: 05 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Timothy K. Andrews, attorney-in-fact

Key filing fact

Cedars Sinai Intellectual Property Co filed Form 4 for Prometheus Biosciences, Inc. on 08 Mar 2023.

Key facts

This page summarizes Cedars Sinai Intellectual Property Co's Form 4 filing for Prometheus Biosciences, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Mar 2023, 20:30.

Change

Previous filing in this sequence was filed on 05 Apr 2022.
Current net transaction value: -$99,120,350.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXDX transaction

Common Stock

Sale

Transaction value: $99,120,350
Shares: -865,000
Change %: -18%
Price: $114.59
Shares after: 4,001,132
Date: 08 Mar 2023
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Cedars Sinai Intellectual Property Co is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The securities reported herein are held of record by Cedars Sinai Intellectual Property Company, which is a wholly owned subsidiary of Cedars-Sinai Medical Center.